期刊
PHARMACEUTICALS
卷 12, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/ph12010007
关键词
tropomyosin receptor kinase; positron emission tomography; neurodegeneration; oncogenic fusions
资金
- Cancer Research Society
- C17 Council
- Natural Science and Engineering Council of Canada (NSERC)
- Weston Brain Institute
- U.S Department of Energy/National Institute of Biomedical Imaging and Bioengineering [DE-SC0012484]
- U.S. Department of Energy (DOE) [DE-SC0012484] Funding Source: U.S. Department of Energy (DOE)
The tropomyosin receptor kinases family (TrkA, TrkB, and TrkC) supports neuronal growth, survival, and differentiation during development, adult life, and aging. TrkA/B/C downregulation is a prominent hallmark of various neurological disorders including Alzheimer's disease (AD). Abnormally expressed or overexpressed full-length or oncogenic fusion TrkA/B/C proteins were shown to drive tumorigenesis in a variety of neurogenic and non-neurogenic human cancers and are currently the focus of intensive clinical research. Neurologic and oncologic studies of the spatiotemporal alterations in TrkA/B/C expression and density and the determination of target engagement of emerging antineoplastic clinical inhibitors in normal and diseased tissue are crucially needed but have remained largely unexplored due to the lack of suitable non-invasive probes. Here, we review the recent development of carbon-11- and fluorine-18-labeled positron emission tomography (PET) radioligands based on specifically designed small molecule kinase catalytic domain-binding inhibitors of TrkA/B/C. Basic developments in medicinal chemistry, radiolabeling and translational PET imaging in multiple species including humans are highlighted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据